Active substance
Potassium chloride
- SFDA 13
- US FDA 149
- Health Canada 9
- US price lines 16
- WHO EML 2
- Safety 28
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| 15% W-V POTASSIUM CHLORIDE FOR INJ. USP | 15 % | Solution for injection · Intravenous use | 1 Vial | SAR 0.70 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| 15% W-V POTASSIUM CHLORIDE FOR INJ. USP | 15 % | Concentrate for solution for infusion · Intravenous use | 1 Ampoule | SAR 2.20 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| 15% W-V POTASSIUM CHLORIDE FOR INJ. USP | 15 % | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 3.95 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| POTASSIUM CHLORIDE | 15 % | Intravenous infusion · Intravenous use | 1 Ampoule | SAR 1.10 | Generic · Prescription | AL RAZI PHARMA INDUSTRIES | Valid |
| POTASSIUM CHLORIDE 7.5% AMP | 7.5 % | Solution for haemodialysis · Intravenous use | 1 Ampoule | SAR 1.45 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| POTASSIUM CHLORIDE 7.5% AMP | 7.5 % | Solution for haemodialysis · Intravenous use | 1 Ampoule | SAR 2.60 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| POTASSIUM CHLORIDE 7.5% AMP | 7.5 % | Solution for haemodialysis · Intravenous use | 1 Ampoule | SAR 1.75 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| Potassium Chloride Extended-Release Tablets USP | 600 mg | Modified-release film-coated tablet · Oral use | 100 Bottle | SAR 52.80 | Generic · Prescription | Granules Pharmaceuticals Inc | Valid |
| POTASSIUM CHLORIDE 1.5% injection USP | 1.5 % | Intravenous infusion · Intravenous use | 1 Bag | SAR 8.00 | Generic · Prescription | QATAR PHARMA | Withdrawn by regulatory authority · Not Marketed |
| POTASSIUM CHLORIDE 10mEqFTV ADDITIVE INJ | 10 mEq | Solution · Intravenous use | 1 Vial | SAR 8.80 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| POTASSIUM CHLORIDE 20mEq FTV. ADDITIVE | 20 mEq | Solution · Intravenous use | 1 Vial | SAR 4.25 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| POTASSIUM CHLORIDE 7.45% INJ AMP | 7.45 % | Injection · Intravenous use | 20 Ampoule | SAR 63.85 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
| POTASSIUM CHLORIDE STRONG(15%) AMP 10ML | 15 % | Injection · Intravenous use | 1 Bottle | SAR 2.05 | Generic · Prescription | B. BRAUN | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETIC KETOACIDOSIS; DIARRHEA; MULTIPLE MYELOMA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| POTASSIUM CHLORIDE | 2MEQ/ML | injectable · injection | HOSPIRA | Prescription | 16 Mar 1972 |
| POTASSIUM CHLORIDE | 2MEQ/ML | injectable · injection | B BRAUN | Prescription | 21 Mar 1978 |
| POTASSIUM CHLORIDE IN PLASTIC CONTAINER | 2MEQ/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 25 Jan 1985 |
| POTASSIUM CHLORIDE IN PLASTIC CONTAINER | 2MEQ/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 25 Jan 1985 |
| KLOR-CON | 8MEQ; 10MEQ | tablet, extended release · oral | UPSHER SMITH LABS | Prescription | 17 Apr 1986 |
| POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER | 14.9MG/ML; 746MG/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 26 Dec 1989 |
| POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER | 29.8MG/ML; 1.49GM/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 26 Dec 1989 |
| POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER | 2.98GM/100ML | injectable · injection | BAXTER HLTHCARE | Prescription | 26 Dec 1989 |
| POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER | 745MG/100ML; 14.9MG/ML | injectable · injection | OTSUKA ICU MEDCL | Prescription | 30 Nov 1992 |
| POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER | 1.49GM/100ML; 29.8MG/ML | injectable · injection | OTSUKA ICU MEDCL | Prescription | 30 Nov 1992 |
| POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER | 2.98GM/100ML | injectable · injection | OTSUKA ICU MEDCL | Prescription | 30 Nov 1992 |
| KLOR-CON M20 | 20MEQ | tablet, extended release · oral | UPSHER SMITH LABS | Prescription | 20 Nov 1998 |
| KLOR-CON M10 | 10MEQ | tablet, extended release · oral | UPSHER SMITH LABS | Prescription | 20 Nov 1998 |
| KLOR-CON M15 | 15MEQ | tablet, extended release · oral | UPSHER SMITH LABS | Prescription | 20 Nov 1998 |
| POTASSIUM CHLORIDE | 10MEQ; 20MEQ | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 10 Apr 2002 |
| POTASSIUM CHLORIDE | 20MEQ; 10MEQ | tablet, extended release · oral | ADARE PHARMS INC | Prescription | 18 Aug 2004 |
| POTASSIUM CHLORIDE | 8MEQ; 10MEQ | capsule, extended release · oral | ACTAVIS LABS FL INC | Prescription | 2 Jun 2008 |
| POTASSIUM CHLORIDE | 10MEQ | capsule, extended release · oral | AMNEAL PHARMS | Prescription | 22 Feb 2013 |
| POTASSIUM CHLORIDE | 8MEQ; 10MEQ | tablet, extended release · oral | PHARMOBEDIENT | Prescription | 21 Aug 2014 |
| POTASSIUM CHLORIDE | 20MEQ/15ML; 40MEQ/15ML | solution · oral | GENUS LIFESCIENCES | Prescription | 22 Dec 2014 |
| POKONZA | 10MEQ/15ML | solution · oral | GENUS LIFESCIENCES | Prescription | 22 Dec 2014 |
| POTASSIUM CHLORIDE | 20MEQ | for solution · oral | GENUS | Prescription | 19 Aug 2015 |
| POKONZA | 10MEQ; 15MEQ | for solution · oral | GENUS | Prescription | 19 Aug 2015 |
| POTASSIUM CHLORIDE | 8MEQ; 10MEQ | tablet, extended release · oral | PADAGIS US | Prescription | 5 Nov 2015 |
| POTASSIUM CHLORIDE | 10MEQ; 20MEQ | tablet, extended release · oral | NOVEL LABS INC | Prescription | 21 Jan 2016 |
124 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| K+ 45 | 01905740 | 251.6 G / L | SOLUTION · HAEMODIALYSIS | VANTIVE ULC |
| POTASSIUM CHLORIDE FOR HEMODIALYSIS 7.55 | 02529793 | 7.55 G / VIAL | POWDER FOR SOLUTION · HAEMODIALYSIS | CHIEF MEDICAL SUPPLIES LTD |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE | 00402206 | 20 mEq / 10 ML | SOLUTION · INTRAVENOUS | OMEGA LABORATORIES LIMITED |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE | 02480034 | 200 mEq / 100 ML | SOLUTION · INTRAVENOUS | OMEGA LABORATORIES LIMITED |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP | 00037869 | 149 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP | 02485699 | 149 MG / ML | SOLUTION · INTRAVENOUS | B. BRAUN MEDICAL INC |
| POTASSIUM CHLORIDE INJECTION | 02241676 | 10 mEq / 100 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| POTASSIUM CHLORIDE INJECTION | 02241677 | 20 mEq / 100 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| POTASSIUM CHLORIDE INJECTION | 02241679 | 40 mEq / 100 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | KLOR-CON 10 MEQ TABLET | $0.12092 | per EA | 23 Sep 2026 |
| US NADAC | KLOR-CON 10 MEQ TABLET | $0.12092 | per EA | 23 Sep 2026 |
| US NADAC | KLOR-CON 20 MEQ PACKET | $0.47003 | per EA | 23 Sep 2026 |
| US NADAC | KLOR-CON 8 MEQ TABLET | $0.11807 | per EA | 19 Aug 2026 |
| US NADAC | KLOR-CON 8 MEQ TABLET | $0.11807 | per EA | 19 Aug 2026 |
| US NADAC | POKONZA 10 MEQ PACKET | $28.26208 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CHLORIDE 10% (20 MEQ/15 ML) ORAL LIQUID | $0.04085 | per ML | 23 Sep 2026 |
| US NADAC | POTASSIUM CHLORIDE 20% (40 MEQ/15 ML) ORAL LIQUID | $0.07285 | per ML | 23 Sep 2026 |
| US NADAC | POTASSIUM CL 20 MEQ PACKET | $0.62416 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CL ER 10 MEQ CAPSULE | $0.13741 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CL ER 10 MEQ TABLET | $0.0828 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CL ER 10 MEQ TABLET | $0.12716 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 26.2. Solutions correcting water, electrolyte and acid-base disturbances > Parenteral · core
Hypokalaemia
Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL) (EML); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL) (EMLc); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL) (EMLc) - 26.1. Solutions correcting water, electrolyte and acid-base disturbances > Oral · core
Hypokalaemia
Oral > Liquid: powder for solution
Safety signals and safety-related labeling changes
- US FDA 5 Nov 2025 LACTATED RINGER'S IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 5 Nov 2025 LACTATED RINGER'S IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions - US FDA 5 Nov 2025 RINGER'S IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions - US FDA 24 Jul 2025 KABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Jul 2025 PERIKABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Oct 2023 SUTAB — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 8 Sep 2023 PLENVU — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jun 2022 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 13 Jun 2022 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 13 Jun 2022 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 13 Jun 2022 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 6 Apr 2022 MOVIPREP — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 GOLYTELY — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 COLYTE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 COLYTE WITH FLAVOR PACKS — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Potassium chloride
- Dextrose + potassium chloride
- Potassium chloride + sodium chloride
- Calcium chloride + potassium chloride + sodium chloride
- Dextrose + potassium chloride + sodium chloride
- Anhydrous dextrose + potassium chloride + sodium chloride + trisodium
- Calcium chloride + dextrose + potassium chloride + sodium chloride
- Calcium chloride + magnesium chloride + potassium chloride + sodium chloride
- Calcium chloride + potassium chloride + sodium chloride + sodium lactate
- Dextrose + potassium chloride + sodium chloride + sodium citrate
- Dextrose + potassium chloride + sodium chloride + tri
- Macrogol + potassium chloride + sodium bicarbonate + sodium chloride
- Macrogol + potassium chloride + sodium chloride + sodium hydrogen carbonate
- Polyethylene glycol + potassium chloride + sodium bicarbonate + sodium chloride
- Potassium chloride + reserpine + resinamine + thiabutazide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.